Products

During a stroke, brain tissue dies due to lack of oxygen

During the acute stage of a stroke, approximately two million brain cells die per minute. The faster the oxygen supply can be restored, the more of the brain can be saved. This means that faster treatment leads to less brain damage and a faster recovery for the patient. In 85% of stroke cases the stroke is due to a clot and in 15% it is due to bleeding. Ten years ago thrombolytic treatment, an efficient clot buster, was approved as treatment for acute stroke. Thrombolytic treatment must, however, be administered within 4.5 hours of the onset of the stroke to be effective. Also, thrombolytic treatment is detrimental if administered to a patient suffering from a stroke due to bleeding. Due to this, the cause of the stroke has to be determined before thrombolytic treatment can be administered. Today, stroke due to clot or bleeding is differentiated using a CT or MR scan. This is, however, done at the hospital, which means that the lead time from onset of stroke to diagnosis often exceeds 4.5 hours. As a result, only 1-8% of stroke patients receive this highly effective treatment


Products

Medfield Strokefinder R10

Sales of R10, Medfield’s first product, are aimed at leading doctors and researchers in the field of stroke diagnosis. The goal of R10 is to pave the way and build market acceptance for microwave diagnostics through the research preformed by these leaders in the field.

Products

Medfield Strokefinder MD100

MD100 is a diagnostic instrument for use in emergency rooms and ambulances to diagnose the type of stroke, ischemic (clot) or hemorrhagic (bleeding) the patient has suffered from.


Products

Impending Applications

Besides stroke diagnostics, microwave technology has several promising applications with great potential, such as the diagnosis of head injuries. The first clinical study designed to determine Strokefinder’s ability to detect intracranial bleeding is planned to take place at Sahlgrenska University Hospital in 2014.

There is a need for new technology as an alternative to X-ray in several areas. Microwave technology has demonstrated greater contrast between healthy and diseased tissue, and is being developed still further within the research group at Chalmers. This research is led by Medfield’s founder, Mikael Persson and Andreas Fhager.

A shared interest in several applications is the ability to use microwave technology for imaging solutions. Although it is an area of ​​major focus within the research group at Chalmers.